{"commentary":{"count":31,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":15,"podcast":13,"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04862663\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"CAPItello-292","nct_id":"NCT04862663","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=capitello-292-nct04862663. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"CAPItello-292","arms":[{"description":"Capivasertib Plus Palbociclib and Fulvestrant (Ph 1b)","label":"Capivasertib Plus Palbociclib and Fulvestrant","type":"EXPERIMENTAL"},{"description":"Capivasertib Plus Ribociclib and Fulvestrant (Ph 1b)","label":"Capivasertib Plus Ribociclib and Fulvestrant","type":"EXPERIMENTAL"},{"description":"Capivasertib Plus Abemaciclib and Fulvestrant (Ph 1b)","label":"Capivasertib Plus Abemaciclib and Fulvestrant","type":"EXPERIMENTAL"},{"description":"Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)","label":"Capivasertib Plus Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)","type":"EXPERIMENTAL"},{"description":"Fulvestrant and investigator's choice of CDK4/6i (palbociclib or ribociclib) (Ph III)","label":"Fulvestrant and Investigator's choice of CDK4/6i (palbociclib or ribociclib)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2029-08-14","type":"ESTIMATED"},"conditions":["Locally Advanced (Inoperable) or Metastatic Breast Cancer"],"enrollment":{"count":893,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Capivasertib","type":"DRUG"},{"name":"Fulvestrant","type":"DRUG"},{"name":"Palbociclib","type":"DRUG"},{"name":"Ribociclib","type":"DRUG"},{"name":"Abemaciclib","type":"DRUG"}],"last_update":"2026-08-17","lead_sponsor":"AstraZeneca","official_title":"A Phase Ib/III, Open-label, Randomised Study of Capivasertib Plus CDK4/6 Inhibitors and Fulvestrant Versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-11-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol.","timeFrame":"Within the first 28 day cycle."},{"measure":"Phase Ib: 2. The number of participants with treatment-related adverse events.","timeFrame":"From baseline up to approximately 36 months."},{"measure":"Phase Ib: 3. The number of participants with treatment-related serious adverse events.","timeFrame":"From baseline up to approximately 36 months."},{"measure":"Phase III: 1. Progression Free Survival (PFS).","timeFrame":"Up to approximately 47 months."}],"references":[],"start_date":{"date":"2021-05-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)","url":"https://clinicaltrials.gov/study/NCT04862663"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/capitello-292-nct04862663"}